1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Upper Tract Urothelial Carcinoma: new trials by email Literature Review of Upper Tract Urothelial Carcinoma trials Research Report on Upper Tract Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma Disitamab Vedotin (RC48), radiotherapy, Gemcitabine (1000 mg/m2) - Upper Tract Urothelial Carcinoma | Phase 3 | Recruiting | Peking University First Hospital | 192 | 2026-05-01 | 2026-09-28 |
Carboplatin (1) · Gemcitabine (1) · RC48 antibody (1) · Radiotherapy (1) · disitamab vedotin (1)
Peking University First Hospital (1)
China (1)